As per Regulation 34(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are submitting Annual Report for Financial year 2024-25 including Notice of 43rd Annual ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivanza Biosciences has submitted its Annual Report for FY 2024-25 along with the Notice for its 43rd Annual General Meeting, scheduled for Thursday, September 25, 2025 at 3:00 p.m. through video conferencing. Shareholders will consider adoption of audited standalone and consolidated financial statements for the year ended March 31, 2025, and the re-appointment of Mr. Parikh H.A. as a Director retiring by rotation. Two special business items seek shareholders' approval to regularise Mr. Hitesh Pradeep Rijwani as a Non-Executive Independent Director (5-year term) and Mr. Sarang Bharatbhai Pathak as a Non-Executive Non-Independent Director. The notice also seeks approval to appoint Mr. Chintan K. Patel as Secretarial Auditor for five years from FY 2025-26 to FY 2029-30, and most notably, to alter the Main Object Clause of the Memorandum of Association to add new business areas including agro products, solar and renewable energy, real estate, drones, IT, data centres, cloud services, and EPC/turnkey projects — a significant shift beyond the company's original biosciences focus. Remote e-voting opens on September 22, 2025 and closes on September 24, 2025, with the cut-off date being September 19, 2025.
The proposed MOA alteration is the most material item for shareholders — if approved, it allows Vivanza to diversify well beyond biosciences into energy, real estate, IT, and infrastructure businesses, which could materially change the company's future revenue mix and risk profile. Director changes and the new 5-year secretarial auditor appointment are routine governance items with limited impact on stock price.